Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04030559
Recruitment Status : Recruiting
First Posted : July 24, 2019
Last Update Posted : April 3, 2020
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Janssen, LP
Information provided by (Responsible Party):
University of California, Davis

Brief Summary:
This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or disease Intervention/treatment Phase
ATM Gene Mutation BRCA1 Gene Mutation BRCA2 Gene Mutation BRIP1 Gene Mutation CDK12 Gene Mutation CHEK1 Gene Mutation CHEK2 Gene Mutation DNA Damage Response Gene Mutation DNA Repair Gene Mutation FANCA Gene Mutation FANCD2 Gene Mutation FANCL Gene Mutation GEN1 Gene Mutation NBN Gene Mutation Prostate Carcinoma RAD51 Gene Mutation RAD51C Gene Mutation Drug: Niraparib Drug: Niraparib Tosylate Monohydrate Procedure: Radical Prostatectomy Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess the impact of neoadjuvant niraparib tosylate monohydrate (niraparib) therapy prior to radical prostatectomy (RP) on pathologic tumor stage, frequency of lymph node metastases and positive margin rates for patients undergoing radical prostatectomy for high-risk, clinically localized prostate cancer with alterations in DNA repair pathways.

SECONDARY OBJECTIVE:

I. To assess 5-year biochemical recurrence in subjects with high-risk prostate cancer and DNA-damage response defects after prostatectomy.

OUTLINE:

Patients receive niraparib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Following completion of treatment, patients then undergo standard of care surgery.

After completion of study treatment, patients are followed up at 30 days, every 3 months for 2 years, and then every 6 months for up to 3 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of PARP Inhibitor Niraparib for Men With High Risk Prostate Cancer and DNA Damage Response Defects
Actual Study Start Date : February 25, 2020
Estimated Primary Completion Date : August 1, 2024
Estimated Study Completion Date : February 1, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Treatment (niraparib)
Patients receive niraparib PO QD on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Following completion of treatment, patients then undergo standard of care surgery.
Drug: Niraparib
Given PO
Other Names:
  • MK-4827
  • MK4827

Drug: Niraparib Tosylate Monohydrate
Given PO
Other Name: Zejula

Procedure: Radical Prostatectomy
Undergo standard of care surgery
Other Name: Prostatovesiculectomy




Primary Outcome Measures :
  1. Pathologic response rate (pRR) [ Time Frame: At the time of radical prostatectomy procedure ]

    The study will assess the impact of neoadjuvant niraparib therapy prior to radical prostatectomy (RP) on pathologic tumor stage, frequency of lymph node metastases and positive margin rates for patients undergoing radical prostatectomy for high-risk, clinically localized prostate cancer with alterations in deoxyribonucleic acid (DNA) repair pathways. Pathologic

    complete response (PCR) defined as no tumor identified on hematoxylin and eosin (H&E) stained sections will be assessed; minimal residual disease (MRD) will be defined as tumor clusters limited to < 5 mm and confined to prostate gland. Exact 95% confidence intervals for pRR and other binary outcomes will be calculated using the Clopper-Pearson method. Response rates will be compared between patients with biallelic and monoallelic loss using Fisher's Exact Test.



Secondary Outcome Measures :
  1. Biochemical prostate specific antigen (PSA) progression free survival [ Time Frame: Up to 5 years ]
    Median biochemical progression free survival (bPFS) and quartiles (when reached) will be calculated from Kaplan-Meier estimates, and 95% confidence intervals will be calculated using Greenwood's formula.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to understand and willingness to sign an informed consent form
  • Ability to adhere to the study visit schedule and other protocol requirements
  • Patients must have histologically or cytologically confirmed prostate cancer that is clinically localized as defined by negative cross-section imaging and/or bone scan, and classified as high or high risk per National Comprehensive Cancer Network (NCCN) guideline
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1
  • Life expectancy >= 10 years
  • Men who have selected radical prostatectomy as the primary treatment for their prostate cancer
  • Prostate cancer tumors with alterations in key DNA repair genes identified on Foundation One assay. This will include at least one alteration in a gene involved in DNA repair primarily through the homologous recombination pathway including BRCA1/2, ATM, CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, RAD51c, and BRIP1. Mutations will be selected that are known or likely pathogenic. Mean allele frequencies will be assessed to estimate mono versus biallelic loss of function. Patients with biallelic deletions or mutations will be prioritized for inclusion to make up at least 30% of the enrollment (i.e., 10 patients) to gauge response in this group over monoallelic loss. Final inclusion will be determined by the principal investigator
  • Must be able to swallow whole capsules
  • To avoid risk of drug exposure through the ejaculate, male subjects (even if they have undergone a successful vasectomy) must agree while on study therapy (including during dose interruptions) and for 3 months following the last dose of study drug to:

    • Use a condom during sexual activity or practice complete sexual abstinence
    • Not donate sperm
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (obtained =< 14 days of the first study treatment)
  • Platelet count >= 100 x 10^9/L (obtained =< 14 days of the first study treatment)
  • Hemoglobin >= 9 g/dL (may have been transfused) (obtained =< 14 days of the first study treatment)
  • Total bilirubin level =< 1.5 x the upper limit of normal (ULN) range (obtained =< 14 days of the first study treatment)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver) (obtained =< 14 days of the first study treatment)
  • International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (for patients on anticoagulation they must be receiving a stable dose for at least 1 week prior to randomization) (obtained =< 14 days of the first study treatment)
  • Creatinine clearance > 30 mL/min by Cockcroft-Gault formula (or local institutional standard method) (obtained =< 14 days of the first study treatment)

Exclusion Criteria:

  • Any condition that would prohibit the understanding or rendering of informed consent
  • Prior treatment for prostate cancer
  • Prior treatment with a PARP inhibitor
  • Prior treatment with androgen deprivation therapy (luteinizing hormone-releasing hormone [LHRH] agonist/antagonist), antiandrogen (e.g., bicalutamide, nilutamide, enzalutamide, apalutamide), or androgen synthesis inhibitor (e.g., abiraterone, orteronel)
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
  • Uncontrolled concomitant disease that in the opinion of the investigator would interfere with the patient's safety or compliance on trial
  • Severe infection that in the opinion of the investigator would interfere with the patient's safety or compliance on trial within 4 weeks prior to enrollment
  • Known allergies, hypersensitivity, or intolerance to niraparib or its excipients (refer to investigator's brochure)
  • Known disorder affecting gastrointestinal absorption
  • Corrected QT interval by the Fridericia correction formula (QTcF) on the screening electrocardiography (ECG) > 450 msec
  • Receiving concomitant medications that prolong QTc and are unable to discontinue use while receiving study drug
  • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
  • Known human immunodeficiency virus (HIV) positive subjects with 1 or more of the following:

    • Not receiving antiretroviral therapy
    • A change in antiretroviral therapy within 6 months of the start of screening (except if, after consultation with the sponsor, a change is made to avoid a potential drug-drug interaction with the study drug)
    • Receiving antiretroviral therapy that may interfere with the study drug (consult the principal investigator [PI] for review of medication prior to enrollment)
    • CD4 count < 350 at screening
    • An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04030559


Locations
Layout table for location information
United States, California
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Marc Dall'Era    916-734-3771    mdallera@ucdavis.edu   
Principal Investigator: Marc Dall'Era         
Sponsors and Collaborators
University of California, Davis
National Cancer Institute (NCI)
Janssen, LP
Investigators
Layout table for investigator information
Principal Investigator: Marc Dall'Era University of California, Davis
Layout table for additonal information
Responsible Party: University of California, Davis
ClinicalTrials.gov Identifier: NCT04030559    
Other Study ID Numbers: 1412676
NCI-2019-04365 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
UCDCC#279 ( Other Identifier: University of California Davis Comprehensive Cancer Center )
P30CA093373 ( U.S. NIH Grant/Contract )
First Posted: July 24, 2019    Key Record Dates
Last Update Posted: April 3, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Niraparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents